FibroBiologics grants options to general counsel

FibroBiologics, Inc. reported a routine equity compensation move for its General Counsel, Ruben A. Garcia.

Rhea-AI Filing Summary

FibroBiologics, Inc. reported a routine equity compensation move for its General Counsel, Ruben A. Garcia. On May 4, 2026, he was granted a stock option covering 61,607 shares of common stock at an exercise price of $1.38 per share, expiring on May 4, 2036.

According to the filing, one quarter of the option will vest on the one-year anniversary of the grant date, with the remaining shares vesting in 36 equal monthly installments, assuming he remains in continuous service. Following this grant, his reported derivative holdings consist of options for 61,607 underlying shares.

Insider Trade Summary

Grant/Award: 61,607 shares

Grant/Award 1 txn

Insider GARCIA RUBEN A

Role General Counsel

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	61,607	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 61,607 contracts (Direct)

Footnotes (1)

1. F1. On May 4, 2026, the reporting person was granted an option to purchase 61,607 shares of common stock. One fourth (1/4th) of the option shares shall vest on the one-year anniversary of the grant date, and the remaining balance of the option shares shall vest in 36 equal consecutive monthly installments thereafter until fully vested so long as the reporting person remains in continuous service through such applicable vesting periods.

Key Figures

Option grant size: 61,607 shares Exercise price: $1.38 per share Expiration date: May 4, 2036 +3 more

6 metrics

Option grant size 61,607 shares Stock option covering common stock

Exercise price $1.38 per share Stock option strike price

Expiration date May 4, 2036 Option term end date

Post-grant derivative holdings 61,607 underlying shares Total options held after transaction

Initial vesting cliff 25% after one year One-fourth vests on first anniversary

Remaining vesting schedule 36 monthly installments After initial one-year cliff

Key Terms

Stock Option (Right to Buy), derivative, exercise price, vesting, +1 more

5 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

derivative financial

"transaction_type: derivative"

A derivative is a financial contract whose value depends on the price or performance of another asset or measure — for example a stock, index, interest rate, commodity, or currency. Investors use derivatives like insurance or leveraged bets to hedge risk, speculate, or gain exposure without owning the underlying asset; they can protect portfolios but also amplify losses and introduce counterparty and market risk.

exercise price financial

"conversion_or_exercise_price: 1.3800"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"option shares shall vest on the one-year anniversary"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

continuous service financial

"so long as the reporting person remains in continuous service"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did FibroBiologics (FBLG) disclose in this Form 4 filing?

FibroBiologics disclosed that its General Counsel, Ruben A. Garcia, received a stock option grant for 61,607 shares. The option is part of his equity compensation and vests over time, aligning his interests with long-term company performance.

How many FibroBiologics (FBLG) shares are covered by the new option grant?

The new option grant covers 61,607 shares of FibroBiologics common stock. These are not shares he owns today but rights to buy shares in the future at a fixed exercise price if vesting and service conditions are met.

What is the exercise price and expiration date of the FibroBiologics option?

The option granted to Ruben A. Garcia has an exercise price of $1.38 per share and expires on May 4, 2036. He can choose to exercise the option after vesting, as long as it is done before this expiration date.

How does the FibroBiologics (FBLG) option for Ruben A. Garcia vest?

The option vests over four years. One fourth of the 61,607 shares vests on the first anniversary of the grant date. The remaining shares then vest in 36 equal monthly installments, assuming he continues providing service to the company.

Is the FibroBiologics Form 4 transaction a market purchase or sale?

No, this Form 4 does not show a market purchase or sale. It reports a grant of stock options to the General Counsel as compensation, with an exercise price set at $1.38 and no cash changing hands at grant.

How many derivative securities does Ruben A. Garcia hold after this grant?

After this grant, the filing shows Ruben A. Garcia holding derivative securities representing 61,607 underlying shares. These are stock options, giving him the right to buy FibroBiologics common shares if he exercises them in the future.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/04/2026 - 07:00 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

GARCIA RUBEN A

(Last) (First) (Middle)

C/O FIBROBIOLOGICS, INC.

9350 KIRBY DRIVE, SUITE 300

(Street)

HOUSTON TEXAS 77054

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
FibroBiologics, Inc. [ FBLG ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	General Counsel

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/04/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$1.38	05/04/2026		A		61,607		(1)	05/04/2036	Common Stock	61,607	$0	61,607	D

Explanation of Responses:

1. On May 4, 2026, the reporting person was granted an option to purchase 61,607 shares of common stock. One fourth (1/4th) of the option shares shall vest on the one-year anniversary of the grant date, and the remaining balance of the option shares shall vest in 36 equal consecutive monthly installments thereafter until fully vested so long as the reporting person remains in continuous service through such applicable vesting periods.

	/s/ Ruben A. Garcia	05/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)